Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612901 | 0.96 | LMNA (0.67) | MAPTALDH1A1LMNASLC6A5SMN1; SMN2 | |
| SCHEMBL29803356 | 0.87 | ALDH1A1 (0.67) | MAPTALDH1A1LMNASLC6A5SMN1; SMN2 | |
| SCHEMBL6808636 | 0.87 | ALDH1A1 (0.67) | MAPTALDH1A1LMNASLC6A5SMN1; SMN2 | |
| SCHEMBL7985113 | 0.85 | ALDH1A1 (0.64) | MAPTALDH1A1LMNASMN1; SMN2MAPK1 | |
| SCHEMBL30962706 | 0.85 | ALDH1A1 (0.64) | MAPTALDH1A1LMNASLC6A5SMN1; SMN2 | |
| SCHEMBL7980470 | 0.85 | ALDH1A1 (0.64) | MAPTALDH1A1LMNASLC6A5SMN1; SMN2 | |
| SCHEMBL31639893 | 0.84 | ALDH1A1 (0.63) | MAPTALDH1A1LMNASLC6A5MAPK1 | |
| SCHEMBL1611598 | 0.84 | LMNA (0.63) | MAPTALDH1A1LMNASLC6A5SMN1; SMN2 | |
| SCHEMBL6495866 | 0.84 | ALDH1A1 (0.63) | MAPTALDH1A1LMNASLC6A5MAPK1 | |
| SCHEMBL3258234 | 0.82 | MAPT (0.65) | MAPTALDH1A1LMNASLC6A5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362010-B2 | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-01-29 | — | — | US | disclosed |
| EP-2432770-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2012-03-28 | — | — | EP | disclosed |
| US-20100292220-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-11-18 | — | — | US | disclosed |
| WO-2010125136-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292220-A1 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR1D, HTR4 | MAPT 4695/4885ALDH1A1 1551/4885LMNA 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.